Comparison of bleeding time changes in essential hypertension patients on losartan or amlodipine: a prospective observational study


  • Narendranath S. Department of Pharmacology,Medical College, Davanagere-577004, Karnataka, India
  • Srinivas LD Department of Pharmacology,Medical College, Davanagere-577004, Karnataka, India
  • Arun S. Department of Pharmacology,Medical College, Davanagere-577004, Karnataka, India
  • Shashikala GH Department of Pharmacology,Medical College, Davanagere-577004, Karnataka, India
  • Pallavi MK Department of Pharmacology,Medical College, Davanagere-577004, Karnataka, India
  • Suresh SR Department of Medicine JJM, Medical College, Davanagere-577004, Karnataka,India
  • Imran Maniyar Department of Pharmacology,Medical College, Davanagere-577004, Karnataka, India



Losartan, Amlodipine, Hypertension, Bleeding time, Antiplatelet activity


Background: Hypertension leads to vascular damage due to high pressure exerted on arteriolar wall and also promotes atherothrombosis in large and medium sized blood vessels. Thrombosis is an extension of haemostasis and platelets have a crucial role in the formation of atherothrombosis. Increased platelet activity is a risk factor in hypertensive patients and leads to cardio- and cerebrovascular events and target organ damage. Anti-platelet aggregatory treatment in these high risk patients have become a crucial step in their treatment. Recent data indicate that angiotensin II type 1 blockers or AT1 receptor blockers (ARBs) like Losartan and dihydropyridine class of L-type calcium channel antagonist like Amlodipine have anti- platelet activity. These two classes of drugs are frequently administered in hypertensive either alone and in combinations. This study aims to compare the anti-platelet activity of Losartan and Amlodipine. Anti-platelet activity in addition to anti-hypertensive activity of these drugs would be beneficial in treating hypertensive who are at high risk of atherosclerosis and atherothrombosis, if they are selectively prescribed these agents.

Methods: This was an observational study. Sixty (n=60) patients diagnosed with essential hypertension, attending medicine outpatient department of a tertiary care hospital were enrolled in the study. Out of them thirty (n=30) were patients who were prescribed losartan. Rest of the patients (n=30) were ones prescribed amlodipine. It was ensured that the patients of both the groups were on respective medication for at least one month. Another thirty (n=30) normotensive subjects acted as control. The bleeding time was evaluated for all three groups using Duke method of bleeding time estimation.

Results: Data was analysed using SPSS software version 20. One way ANOVA was used to analyse the data. This was followed by post hoc Tukey’s test. The mean bleeding time(in minutes) of Losartan group was 2.583±0.263 SD, Amlodipine group was 2.214±0155 SD and control group was 1.998±0.198 SD. Statistically significant p value of <0.001 was observed in losartan and amlodipine groups.

Conclusions: Our study shows that the mean bleeding time of Losartan group and amlodipine group were significantly higher than that of Control group. It was further observed that the mean bleeding time of losartan was higher than that of amlodipine group indicating a better antiplatelet action by losartan than amlodipine. Additional antiplatelet activity could be desirable to treat hypertensive patients with high atherothrombotic and/or thromboembolic risk.


Gkaliagkous E, Passacquale G, Douma S, Zamboulis C, Ferro A. Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens. 2010;23(3):229-36.

Sato Y, Fuji S, Imagawa S, Ohmura K, Ohmura Y, Andoh Y, et al. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb. 2007;14(1):31-5.

Cozzi MR, Guglielmini G, Battistin M, Momi S, Lombardi E, Miller EC, et al. Visualization of nitric oxide production by individual platelets during adhesion in flowing blood. Blood. 2015;125(4):697-705.

Harrison T, Kasper D, Fauci A, Hauser S, Longo D, Jameson J, et al. Editors Harrison’s: principle of internal medicine. 19th ed. New York (USA): McGraw Hill Education; 2015:745.

Shankarishan P, Bora PK, Ahmed G, Mahanta J. Endothelial nitric oxide synthase gene polymorphisms and the risk of hypertension in an Indian population. Bio Med Research International. 2014(2014):1-11.

Yang GJ. Antiplatelet therapy in patients with hypertension. Journal of Translational Internal Medicine. 2013;1(1):28.

Radu D, Rudic, Sessa WC. Human genetics’99: the cardiovascular system nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet. 1999;64:673-7.

Richard AP, Wenche JY, Joaquin JJ, Lucia MM, Lawrence LH, Madelyn V, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003;41:211-7.

Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by NO release. Hypertension. 2002;40:521-7.

Sakamoto T, Kudoh T, Sakamoto K, Matsui K, Ogawa H. Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation. Hypertension Research. 2014;37:513-8.

Monton M, Jimenez A, Nunez A, Lopez-Blaya A, Farre J, Gomez J, et al. Comparative effect of angiotensin II AT-type-1 receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol. 2000;35(6):906-13.

Tz-Chong C. New mechanisms of antiplatelet activity of nifedipine, an L-type calium channel blocker. BioMedicine. 2014;4(3):17-24.

Mancia G, Fagard R, Narkiewicz K. ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159- 219.

Charbek E. Bleeding time: reference range, interpretation, collection and panels; 2016. Available at

Kumar V, Abbas AK, Aster JC. Robbins: basic pathology. 9th ed. Philadelphia (PA): Elsevier Saunders; 2013:450.

He Y, Si D, Yang C, Wi L, Li B, Ding M. The effects of amlodipine and S (-)-amlodipine on vascular endothelial function in patients with hypertension. Am J Hypertens. 2014;27(1):27-31.

Lincoln RP. Guanylyl cyclase structure function and regulation. Cell Signal. 2011;23(12):1921-6.

Thiriet M. Biomathematical and biomechanical modeling of circulatory and ventilator systems 4: intracellular signalling mediators in the circulatory and ventilator systems. USA (NY): Springer Science+Business Media; 2013:846.

Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW. Editors principles of pharmacology: the pathophysiologic basis of drug therapy. 3rd ed. Philadelphia (PA). Lippincott Williams and Wilkins; 2012:362.

Shih CY, Lin IH, Ding JC, Chen FC, Chou TC. Antiplatelet activity of nifedipine is mediated by inhibition of NF-κB activation caused by enhancement of PPAR-β/-γ activity. Br J Pharmacol. 2014;171(6):1490-500.




How to Cite

S., N., LD, S., S., A., GH, S., MK, P., SR, S., & Maniyar, I. (2017). Comparison of bleeding time changes in essential hypertension patients on losartan or amlodipine: a prospective observational study. International Journal of Basic & Clinical Pharmacology, 5(4), 1555–1558.



Original Research Articles